louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01757379: Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans
Official title: Evaluation of the Bioavailability and Production of Short Chain Fatty Acids in the Colon. A Stable Isotope Study in Healthy Humans.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Short Chain Fatty Acids Bioavailability
Keywords: Short chain fatty acids
Acetate
Propionate
Butyrate
Bioavailability
Lead sponsor: KU Leuven
Sponsor class: OTHER
First posted: 2012-12-28
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to evaluate the bioavailability of acetate, propionate and butyrate in healthy humans using a stable isotope technology.

In addition the level of acetate, propionate and butyrate production from inulin will be determined using the principle of isotope dilution.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* Regular dietary pattern (3 meals/day)
* Age: 18-65y
* BMI: 18,5-27 kg/m2

Exclusion Criteria:

* Intake of antibiotics 1 month prior to the study
* Abdominal surgery in the past, with the exception of appendectomy
* Intake of medication influencing the gastro-intestinal system 14 days prior to the study
* In treatment at a dietician
* Intake of pre- and/or probiotics
* Exposure to radioactivity 1 year prior to the study
* Serious chronic disease of the gastrointestinal tract
* Use of medication that affects the gastro-intestinal tract during the last 2 weeks prior to the study
* Pregnancy, pregnancy desire or lactation
* Blood donation during the last 3 months prior to the study
* Diabetes (type 1 or 2)
* Aberrant hemoglobin level (Hb) in blood. Normal between 14.0 and 18.0 g/dL for men and between 12.0 and 16.0 g/dL for women

Primary outcomes:
measure: Concentrations of the short chain fatty acids (acetate, propionate and butyrate) in plasma and urine samples
timeFrame: 12 hours each test day and 4 test days/volunteer
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: KU Leuven/ UZ Leuven
state: Vlaams-Brabant
Study officials:
affiliation: KU Leuven
name: Kristin Verbeke, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00652379: Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Official title: Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acromegaly
Insulin Resistance
Impaired Glucose Tolerance
Keywords: Acromegaly
Insulin sensitivity
Glucose tolerance
Body composition
Growth Hormone
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital Skejby
name: Aarhus University Hospital
name: The Research Council for Health and Disease, Denmark
First posted: 2008-04-03
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy.

Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.


Eligibility criteria: Inclusion Criteria:

* Age \> 18
* Diagnosed with acromegaly
* Safe anticonceptive for fertile women
* Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH \< 0.5 µg/l.)

Exclusion Criteria:

* Pregnancy
* Liver disease
* Diabetes mellitus type I
* Magnetic or electronic implants

Primary outcomes:
measure: Insulin sensitivity
timeFrame: 0 and after 24 weeks
Secondary outcomes:
measure: Glucose tolerance
timeFrame: 0 and after 24 weeks
measure: Symptoms, QoL questionaire
timeFrame: 0, 12 and 24 weeks
measure: Intrahepatic and intramyocellular fat
timeFrame: 0 and 24 weeks
measure: Substrate metabolism
timeFrame: 0 and 24 weeks
Other outcomes:
Locations:
city: Aarhus C
country: Denmark
facility: Department of Endocrinology, Aarhus University Hospital
state: Aarhus
Study officials:
affiliation: Aarhus University Hospital
name: Jens Otto L. Jørgensen, MD Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02312479: Safety and Performance Study of the Nyxoah SAT System for Treating OSA
Official title: Safety and Performance Study of the Use of the Nyxoah SAT System for the Treatment of Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: Nyxoah S.A.
Sponsor class: INDUSTRY
First posted: 2014-12-09
Enrollment: 6
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A prospective open-label, single treatment study to assess the safety and the performance of the Nyxoah SAT system for the treatment of Obstructive Sleep Apnea


Eligibility criteria: Inclusion Criteria:

* Diagnosed with moderate to severe Obstructive Sleep Apnea
* Have failed or have not tolerated CPAP treatment
* Willing and capable of providing informed consent
* Willing and capable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires

Exclusion Criteria:

* BMI limits
* Subjects with complete concentric collapse at the soft palate level per endoscopy

Primary outcomes:
measure: Incidence of serious device related adverse events
timeFrame: 6-months post-implantation
measure: Mean change of AHI (Apnea-Hypopnea Index) measured by in-lab polysomnography (PSG) from baseline measurement to 6-months post-implantation
timeFrame: 6-months post-implantation
Secondary outcomes:
Other outcomes:
Locations:
city: Edegem
country: Belgium
facility: Antwerp University Hospital
city: Mannheim
country: Germany
facility: Universitäts-HNO-Klinik Mannheim
Study officials:
affiliation: Universitäts-HNO-Klinik Mannheim
name: Joachim T Maurer, OA Dr. med.
role: PRINCIPAL_INVESTIGATOR
affiliation: Universiteit Antwerpen
name: Evert Hamans, PhD Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02619279: A Livelihood Intervention for Impoverished Women and Children in Rural Uganda
Official title: A Livelihood Intervention for Impoverished Women and Children in Rural Uganda: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Indigency
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Mbarara University of Science and Technology
First posted: 2015-12-02
Enrollment: 150
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The objective of the study is to determine whether a livelihood intervention can improve health and schooling outcomes of the children of woman participating in a livelihood intervention in rural Uganda.


Eligibility criteria: Inclusion Criteria:

* All children under 18 years

Exclusion Criteria:

* Adults older than 18 years

Primary outcomes:
measure: Stunting based on Anthropometric Measurements
timeFrame: 12 months
measure: Weight-for-Height based on Anthropometric Measurements
timeFrame: 12 months
measure: Raven's Colored Progressive Matrices test
timeFrame: 12 months
measure: Mullen Early Learning Scales
timeFrame: 12 months
measure: Home Observation of the Measurement of Environment Scale
timeFrame: 12 months
Secondary outcomes:
measure: Child Educational Investment Scale
timeFrame: 12 months
measure: Child Non-Educational Investment Scale
timeFrame: 12 months
measure: Mother's Educational Investment Scale
timeFrame: 12 months
measure: Mother's Aspirations for Child Education Scale
timeFrame: 12 months
measure: Mother's Aspirations for Child Career Scale
timeFrame: 12 months
Other outcomes:
Locations:
city: Mbarara
country: Uganda
facility: Mbarara University of Science and Technology
Study officials:
affiliation: Massachusetts General Hospital
name: Alexander C Tsai, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mbarara University of Science and Technology
name: Bernard Kakuhikire, MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02430779: Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms
Official title: Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Pelvic and Ureteral Neoplasms
Keywords: irreversible electroporation
Unresectable Renal Pelvic and Ureteral Neoplasms
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
First posted: 2015-04-30
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Renal Pelvic and Ureteral Neoplasms.

Detailed description: By enrolling patients with unresectable Renal Pelvic and Ureteral Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Renal Pelvic and Ureteral Neoplasms.

Eligibility criteria: Inclusion Criteria:

* Renal Pelvic and Ureteral Neoplasms diagnosed by positive biopsy or non-invasive criteria,
* Not suitable for surgical resection,
* Eastern Cooperative Oncology Group (ECOG) score of 0-1,
* A prothrombin time ratio \> 50%,
* Platelet count \> 80x10\^9/L,
* Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
* Able to comprehend and willing to sign the written informed consent form (ICF),
* Have a life expectancy of at least 3 months.

Exclusion Criteria:

* Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
* Any active implanted device (eg Pacemaker),
* Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
* Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
* Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Primary outcomes:
measure: Number of participants with Adverse events
timeFrame: 6 month
Secondary outcomes:
measure: Percentage of lesions that show no sign of recurrence 12 months after IRE
timeFrame: 12 months
measure: Voltage (A minimum and maximum range of voltage for safe and effective IRE)
timeFrame: 3 months
measure: Progress free disease (PFS)
timeFrame: 12 months
measure: Overall survival (OS)
timeFrame: 36 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Biological treatment center in Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital
name: Lizhi Niu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01977079: Procalcitonin and Threatened Premature Delivery
Official title: Procalcitonin and Threatened Premature Delivery
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pregnancy
Premature Delivery
Keywords: pregnancy
premature birth
procalcitonin
Lead sponsor: Centre Hospitalier Departemental Vendee
Sponsor class: OTHER
First posted: 2013-11-06
Enrollment: 131
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Among all patients hospitalized for Threatened Premature Delivery (TPD), the rate of premature birth (PB) before 37 weeks is about 42%, which reflects the inability to accurately identify patients at high risk of PB. Currently, no clinical or biological marker is recognized as the most reliable in predicting the real risk of AP in case of MAP.

The purpose of this study is to improve the knowledge of predictors of preterm delivery compared with conventional blood markers by estimating serum procalcitonin according to premature delivery or not in patients hospitalized for preterm labor .


Eligibility criteria: Inclusion Criteria:

* age \> 18 year
* Ongoing pregnancy with a start date of pregnancy known and confirmed by an ultrasound of the 1st Quarter performed between 10 and 14 weeks with a measurement of the crown-rump length
* hospitalization for preterm labor between 24 and 36 weeks of gestation
* Intact membranes,
* not opposed to participate in the study

Exclusion Criteria:

* Pregnancy uncertain term (no early ultrasound)
* Pregnancy combining a condition that can interfere with the assays performed,
* Uterine malformation known
* Multiple pregnancy,
* Premature rupture of membranes,
* Chrorio-amnionitis,
* Fetal malformation known
* Strapping
* GB\> 15000 and CRP\> 10 mg / L,
* No affiliation to a social security scheme.
* Woman with a measure of legal protection

Primary outcomes:
measure: procalcitonin rate
timeFrame: up to 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: La Roche sur Yon
country: France
facility: Centre hospitalier départemental Vendée
Study officials:
affiliation: Centre hospitalier départemental Vendée
name: Guillaume DUCARME, PH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ducarme G, Desroys du Roure F, Le Thuaut A, Grange J, Vital M, Dimet J. Efficacy of serum procalcitonin to predict spontaneous preterm birth in women with threatened preterm labour: a prospective observational study. BMC Pregnancy Childbirth. 2018 Mar 7;18(1):65. doi: 10.1186/s12884-018-1696-2.
Clinical trial NCT02987179: Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis
Official title: Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ESRD
Sleep Apnea
Oxygen Deficiency
Lead sponsor: Renal Research Institute
Sponsor class: OTHER
First posted: 2016-12-08
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chronic hemodialysis patients

Brief summary: The clinical diagnosis of sleep apnea is difficult among ESRD patients since the characteristic clinical features of sleep apnea may be absent and since sleep-related symptoms, such as fatigue and sleepiness, may be attributed to kidney failure. However, the evaluation of patients with possible sleep apnea is the same among ESRD patients as in the general population.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years and able to give written informed consent to the study
* On chronic hemodialysis for ≥ 90 days at time of enrollment
* Ability to read
* Consent to have video recording taken during study visit

Exclusion Criteria:

* Subjects with cognitive impairment to consent
* Sickle cell anemia
* Prescription of nasal oxygen
* Simultaneous participation in another clinical trial that may affect breathing frequency/patterns, blood oxygenation, sleep/wake cycle or other parameters related to the outcomes of interest to this study
* Use of a breathing device, e.g. CPAP
* Central venous catheter used as vascular access for hemodialysis
* Artificial fingernails (may disturb the measurement of the WatchPAT)
* Use of one of the following medications: alpha blockers, short acting nitrates (less than 3 hours before the study).
* Permanent pacemaker
* Sustained non-sinus cardiac arrhythmias.

Primary outcomes:
measure: Identifying Intradialytis desaturation episodes
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Renal Research Institute
state: New York
Study officials:
References:
Clinical trial NCT01593579: Autonomic Phenotype Before and After Akt Inhibition
Official title: Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Diagnosis of Melanoma
Keywords: melanoma
autonomic failure
hypotension
akt therapy
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2012-05-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients will have a diagnosis of Melanoma and be participating in a clinical trial with an arm using oral Akt therapy. Patients will be recruited from the Vanderbilt Ingram Cancer Center.

Brief summary: Some Akt inhibitors have produced functional cardiovascular effects such as marked hypotension that may limit their clinical benefit. There are no current data on whether this autonomic failure presents in humans at clinically used doses. We will test the hypothesis that Akt inhibition causes an acute decrease in sympathetic tone and lowers blood pressure.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a BRAF inhibitor
* Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
* Able and willing to provide informed consent

Exclusion Criteria:

* Factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
* Unable to give informed consent

Primary outcomes:
measure: Drop in systolic blood pressure before and after Akt treatment
timeFrame: 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
References:
Clinical trial NCT04859179: Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women
Official title: Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Spinal Muscular Atrophy
Keywords: spinal muscular atrophy
prenatal screening
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All pregnant women who came to antenatal care clinic at Ramathibodi Hospital, Mahidol University

Brief summary: Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.

Detailed description: Spinal muscular atrophy (SMA) is one of the most common neuromuscular autosomal recessive disorders. The incidence is about 1:10,000 livebirths. There are 5 subgroups base on onset of symptoms and clinical severity. Type 1 is the most severe type which age of onset is 6 months old and life expectancy is less than 1-2 years. SMA carrier frequency is approximately 1/40-1/60. Molecular genetic testing to detect copies number of SMN1 gene is possible with as high as 95% detection rate. Since 2008, American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG) recommended SMA preconceptional and prenatal carrier screening in general population. In Thailand, there are no standard protocol for SMA prenatal carrier screening.

Eligibility criteria: Inclusion Criteria:

* Maternal age \> 18 years
* Singleton pregnancy
* Gestational age ≤ 14 weeks

Exclusion Criteria:

* Refuse to participate the research trial

Primary outcomes:
measure: Rate of acceptance of prenatal carrier screening for spinal muscular atrophy
timeFrame: 12 months
Secondary outcomes:
measure: Factors associated rate of acceptance of prenatal carrier screening for spinal muscular atrophy
timeFrame: 12 months
measure: Copies number of SMN1 and SMN2 genes in pregnant women
timeFrame: 12 months
measure: Carrier frequency among individuals who accepted carrier screening
timeFrame: 12 months
measure: Pregnant women's attitudes toward spinal muscular atrophy and carrier screening
timeFrame: 12 months
Other outcomes:
Locations:
city: Ratchathewi
country: Thailand
facility: Faculty of Medicine, Ramathibodi Hospital, Mahidol University
state: Bangkok
Study officials:
affiliation: Ramathibodi Hospital, Mahidol University
name: Chayada Tangshewinsirikul
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02502279: Lung Recruitment and Postoperative CPAP
Official title: Lung Recruitment and Postoperative CPAP in Pediatric Laparoscopic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anesthesia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2015-07-20
Enrollment: 60
Sex: MALE
Minimum age (years): 6
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: General anesthesia lowers FRC thereby promoting airway closure and absorption atelectasis. Alveolar recruitment manoeuvers recruit collapsed alveoli, increase gas exchange, and improve arterial oxygenation.

Detailed description: General anesthesia lowers FRC thereby promoting airway closure and absorption atelectasis. Alveolar recruitment manoeuvers recruit collapsed alveoli, increase gas exchange, and improve arterial oxygenation. However, the effect of recruitment manoeuvre is short lasting and does not extend to the post operative period. Postoperative CPAP keeps the lung open and can improve oxygenation in the early postoperative period.

Eligibility criteria: Inclusion Criteria:

* Pediatric patients undergoing laparoscopic surgery for abdominal cryptorchidism.

Exclusion Criteria:

* Cardio-respiratory illness.
* Unsatisfactory preoperative peripheral arterial oxygen saturation.
* Unsatisfactory preoperative hemoglobin level.
* Neurological or psychiatric disease.
* Children with a BMI \>95th percentile for age.

Primary outcomes:
measure: (A-a) DO2
timeFrame: 1 hour after extubation
Secondary outcomes:
measure: PaO2
timeFrame: intra-operative and 1hour postoperative
measure: PaCO2
timeFrame: intra-operative and 1hour postoperative
measure: PH
timeFrame: intra-operative and 1hour postoperative
measure: Respiratory mechanics
timeFrame: Intraoperative
measure: non invasive mean arterial pressure
timeFrame: intraoperative and 1hour postoperative
measure: Heart rate
timeFrame: intraoperative and 1hour postoperative
measure: Peripheral arterial oxygenation SPO2%
timeFrame: intraoperative and 1hour postoperative
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Pediatric hospital
state: Assiut governorate
Study officials:
affiliation: Assisstant professor in Anesthesia and intensive care department, faculty of medicine, Assiut university, Egypt
name: Hala S Abdel-Ghaffar, MD
role: PRINCIPAL_INVESTIGATOR
References: